NCT05989425View on ClinicalTrials.gov

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

August 4, 2026

Study Completion Date

August 4, 2026

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

surufatinib

Surufatinib is a tablet in the form of 50mg, oral, once a day.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER